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WT1 interacts with the splicing factor
U2AF65 in an isoform-dependent manner
and can be incorporated
into spliceosomes
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WT1 is essential for normal kidney development, and genetic alterations are associated with Wilms’ tumor,
Denys Drash (DDS), and Frasier syndromes. Although generally considered a transcription factor this study
has revealed that WT1 interacts with an essential splicing factor, U2AF65, and associates with the splicing
machinery. WT1 is alternatively spliced and isoforms that include three amino acids, KTS, show stronger
interaction with U2AF65 in vitro and better colocalization with splicing factors in vivo. Interestingly a
mutation associated with DDS enhanced both −KTS WT1 binding to U2AF65 and splicing-factor
colocalization. These data illustrate the functional importance of WT1 isoforms and suggest that WT1 plays
a role in pre-mRNA splicing.
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Defects in the WT1 gene predispose to childhood kidney
tumors and can also result in Denys Drash (DDS) or Fra-
sier syndromes, in which symptoms include genital mal-
formation and nephropathy (Barbaux et al. 1997; Little
and Wells 1997). WT1 is essential for urogenital devel-
opment, and is expressed in cells that undergo a mesen-
chyme to epithelial transition (Pritchard-Jones et al.
1990; Kreidberg et al. 1993). The gene product has hall-
marks of a transcription factor; four ‘Kru¨ppel-like’ zinc
fingers at its carboxy terminus, and an amino-terminal
transcriptional regulatory domain. The zinc fingers are
related to those of the transcription factor EGR1, and
WT1 can bind to the GC-rich EGR1 DNA-binding site
(Rauscher et al. 1990). WT1 both activates and represses
GC-rich promoters, depending on context (Wang et al.
1993), generating the hypothesis that the protein acti-
vates genes of the epithelial lineage, and represses those
that promote mesenchymal cell proliferation (Hastie
1994). To date, however, no clear in vivo targets for regu-
lation by WT1 have been identified.
The WT1 gene encodes numerous protein isoforms.
Two translational start sites have been identified, a stan-
dard methionine and a non-AUG leucine, which adds 68
amino-terminal residues (Breuning and Pelletier 1996). A
specific nucleotide in the pre-mRNA is apparently ed-
ited, resulting in proteins differing by a single amino acid
(Sharma et al. 1994). The pre-mRNA is also alternatively
spliced (Haber et al. 1991). A first alternative exon en-
codes 17 amino acids that can be inserted towards the
center of the protein, and a second 3 amino acids, KTS,
which can be included between the third and fourth zinc
fingers. The strong conservation of this latter motif
throughout evolution suggests that it plays an important
role (Kent et al. 1995). The KTS insertion reduces both
DNA binding affinity and specificity (Bickmore et al.
1992). DNA binding by WT1 is known to play an impor-
tant function as many DDS patients have mutations that
specifically alter this activity (Little and Wells 1997).
Significantly, Frasier syndrome is associated with WT1
mutations at splice-donor sites that prevent generation
of +KTS isoforms (Barbaux et al. 1997). The isoform ratio
appears constant throughout development (Harber et al.
1991), and the severe phenotype that arises from isoform
imbalance in Frasier syndrome patients indicates that
maintaining appropriate proportions of each protein is
critical for function.
Some surprising clues to potential WT1 function came
from careful examination of cell localization. The pro-
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tein has a distinct nuclear pattern, being found in ‘speck-
les’ and coiled bodies (Larson et al. 1995). This pattern is
characteristic of splicing, rather than transcription, fac-
tors. Indeed staining WT1-expressing cells for both WT1
and splice factors revealed good colocalization (Larson et
al. 1995). Intriguingly more detailed analysis following
transfection of individual WT1 forms revealed a marked,
though not absolute, correlation between isoform and
subnuclear distribution. Isoforms including the KTS mo-
tif colocalized dominantly with splicing factors, whereas
−KTS proteins colocalized better with transcription fac-
tors (Larsson et al. 1995). This illustrates the differences
between the isoforms, and suggests WT1 might not func-
tion exclusively as a transcription factor.
The major components of nuclear speckles and coiled
bodies are splicing proteins. Coiled bodies were de-
scribed originally as nucleolar accessory bodies and may
play a role in splicing-complex assembly, maturation, or
recycling. One coiled-body-specific protein, p80-coilin,
may be central to this process (Bohmann et al. 1995).
Recent evidence has suggested that speckles are dynamic
structures, perhaps representing storage sites from
which splicing factors are recruited (Misteli et al. 1997).
Splicing itself is a complex two-step process, involving
multiple RNA and protein species. Initially U1 snRNP,
of which U170K is a major component, binds to the 58
splice site, and U2AF65 to the 38 splice site. These two
complexes are bridged by SR protein family members
such as SRp20, SC35, and ASF/SF2 (Wu and Maniatis
1993). U2AF65, with its partner U2AF35, promotes an-
nealing of the U2 snRNA to the polypyrimidine tract
adjacent to the 38 splice site, facilitating splicing itself
(Zamore et al. 1992). These proteins display a nuclear
speckled pattern and have several common motifs, in-
cluding arginine/serine-rich RS domains, and RNA rec-
ognition motifs (RRM). There is some evidence from mo-
lecular modeling that WT1 may have an amino-terminal
RRM (Kennedy et al. 1996). Interestingly RNA binding
by WT1 has been demonstrated in vitro, although this
activity mapped to the first zinc finger, which has a
slightly different structure then the remaining three
(Caricasole et al. 1996). As WT1 colocalizes and indeed
coimmunoprecipitates with splicing factors (Larsson et
al. 1995), and has RNA-binding potential, it was clearly
important to test whether WT1 associates directly with
the splicing machinery.
Results
The ability of WT1 to interact directly with components
of the splicing machinery was examined in a yeast two-
hybrid system. Seven proteins were tested, including
the splicing factors U170K, ASF/SF2, SC35, U2AF35,
U2AF65, SRp20, and the coiled-body protein p80-coilin
(Fig. 1A; data not shown). Only U2AF65 was identified as
a potential binding partner, stimulating both growth
without histidine and b-galactosidase activity in a dual-
reporter system. The yeast proteins SNF1 and SNF4 were
used as internal positive and negative controls (Harper et
al. 1993). The observation that WT1 and U2AF65 inter-
act was supported by the finding that in vitro-translated
WT1, but not the related protein EGR1, could complex
with bacterially expressed GST-U2AF65 (Fig. 1B).
To establish whether WT1 and U2AF65 interact in
vivo coimmunoprecipitations were performed from a
mesonephric WT1-expressing cell line, M15 (Larsson et
al. 1995). WT1 was present in U2AF65 immunoprecipi-
tates, above background levels of control precipitations
(Fig. 1C). The two WT1 immunoreactive bands corre-
spond to isoforms initiated at the methionine and leu-
cine starts (lower and higher band, respectively). These
can be further resolved to show proteins containing/
lacking the 17-amino-acid insert. Proteins with/without
the KTS motif cannot be separated by size. WT1 is also a
component of Sm immunoprecipitates (Larsson et al.
1995; Fig. 1C), which comprise a number of different
splicing antigens, U2AF65 coprecipitating among them
(data not shown). Therefore WT1 might form part of a
multimeric complex including U2AF65 and other splic-
ing factors. The ability to detect WT1:U2AF65 interac-
tion by immunoprecipitation was variable and appeared
to be dependent on the method used to prepare the ex-
tracts. This might suggest that only a small proportion of
these proteins are complexed and/or the complex is tran-
sitory. From the relative intensity of the signals, only a
fraction of WT1 appears associated with U2AF65. Sig-
nificantly, the WT1 signal from U2AF65 immunopre-
cipitates is weaker than that from Sm (Fig. 1C), suggesting
that WT1 might interact with other splicing proteins.
WT1 is a complex gene that encodes many proteins.
To investigate whether U2AF65 binding is isoform de-
pendent, the set of major WT1 proteins were tested. The
first plus or minus symbol denotes the presence or ab-
sence of the 17-amino-acid insert, and the second repre-
sents KTS status. The initial yeast two-hybrid assays
suggested that +KTS forms interacted more strongly
with U2AF65 than forms lacking the KTS motif (Fig. 1A;
data not shown). To examine this more closely b-galac-
tosidase activity was measured in independent yeast
colonies. This quantitative analysis indicates the rela-
tive strength of a particular interaction (Estojak et al.
1995). One described previously property of WT1 is ho-
modimerization (Reddy et al. 1995), and this ability was
used as an internal control. Whereas all isoforms showed
similar ability to dimerize, the +KTS proteins showed
stronger binding to U2AF65 than −KTS forms, although
all isoforms showed at least some binding (Fig. 2A). This
effect was not caused by differences in protein levels
(data not shown). The differences in affinity of the WT1
isoforms for U2AF65 also became evident following ti-
tration of the GST binding experiments. At 100 mM salt,
all forms of in vitro-translated WT1 bound broadly
equally to GST–U2AF65 (Fig. 1B). However, at 250 mM
salt, the binding of −KTS protein decreased (Fig. 2B). The
enhanced binding of +KTS isoforms to U2AF65 corre-
lates with their better colocalization with splicing fac-
tors (Larsson et al. 1995).
To map the region of WT1 that interacts with
U2AF65, the protein was divided initially into two,
N180 and C±KTS (Fig. 3A). The abilities of WT1 to
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dimerize and bind U2AF65 were found to be separable.
N180, comprising the first 180 amino acids of WT1,
could dimerize (Reddy et al. 1995), but did not bind
U2AF65 (Fig. 3B). Conversely, the remainder of the pro-
tein was defective for dimerization but retained KTS-
dependent U2AF65 binding (albeit at slightly reduced
levels). Molecular modeling has revealed a potential
RNA recognition motif within the amino terminus of
WT1 (Kennedy et al. 1996). As WT1 binding to U2AF65
is independent of the amino terminus, it follows that
RNA binding through this motif would not be essential
for U2AF65 interaction. Within the remaining carboxy-
Figure 2. U2AF65 binding is influenced by
isoform. (A) Quantitation of b-galactosidase
activity following transformation of yeast
with the indicated constructs. (Solid bars)
U2AF65; (open bars) SNF1; (hatched bars)
WT1+/+ (WT1+/+). (B) WT1 binding to GST–
U2AF65 compared to GST alone under dif-
ferent salt concentrations. (Solid bars) 100
mM; (hatched bars) 250 mM; (open bars) 500
mM.
Figure 1. WT1 interacts with U2AF65.
(A) Yeast two-hybrid analysis. Yeast was
transformed with plasmids encoding the
indicated proteins, and individual colo-
nies grown on Leu−Trp− (left) prior to the
assessment of b-galactosidase activity
(right). (B) In vitro binding assay. The in-
dicated in vitro-translated proteins (left)
were mixed with GST or GST–U2AF65
purified from bacteria, bound protein re-
solved by SDS-PAGE, and detected by
fluorography (right). (C) WT1 coimmuno-
precipitates with U2AF65. WT1-express-
ing M15 cells were immunoprecipitated
with antibodies against the indicated pro-
teins or normal mouse IgG, the com-
plexes resolved by SDS-PAGE, and the
presence of WT1 determined by Western
blotting.
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terminal portion, deletion of finger 1 (CDF1), another
proposed RNA-interacting region (Caricasole et al. 1996),
did not impair U2AF65 binding, displaying, if anything,
increased association. Significantly, removal of all the
zinc finger motifs (CTF0) resulted in loss of binding,
whereas the finger region alone (F + KTS), displayed only
a weak interaction. These results suggest that the zinc
fingers provide elements critical for binding, but it seems
likely that the interaction is stabilized by other residues.
This view is supported by additional in vitro binding
experiments (data not shown).
DDS patients often have a missense mutation affect-
ing a single residue within the WT1 zinc-finger region
that impairs DNA binding (Little and Wells 1997). As the
zinc-finger region of WT1 makes a significant contribu-
tion to U2AF65 binding, it was important to determine
whether this mutation affected interaction. Comparison
of +KTS and −KTS DDS mutant proteins revealed that
the alteration increased affinity of the −KTS form for
U2AF65. Dimerization ability, protein levels, and the
properties of the +KTS protein appeared unaffected (Fig.
3C; other data not shown).
The relationship between nuclear distribution and af-
finity for U2AF65 is striking; strong U2AF65-binding
WT1 proteins show good colocalization with splicing
factors. It was therefore important to examine the stain-
ing pattern of mutant proteins. Interestingly the −KTS
Drash mutant, which has increased U2AF65-binding po-
tential, showed an apparent shift in nuclear distribution,
displaying enhanced colocalization with splicing factors
like +KTS isoforms, independently of expression level
(Fig. 3D; data not shown). U2AF65 binding is not a pre-
requisite for this speckled distribution of WT1, because
TF0 lost U2AF65 binding but still largely colocalizes
with splicing factors (Fig. 3B and D).
Having examined the region of WT1 responsible for
interaction with U2AF65, attention shifted to the recip-
rocal domain. U2AF65 has three RRMs at its carboxy
terminus (Fig. 4A). Removal of this region (DRRM) did
not impair either the ability to interact with WT1 or
U2AF35 (Fig. 4B). U2AF65 also has an essential amino-
terminal R/S rich ‘effector’ domain separated from the
RRM by a ‘linker’ region that binds partner proteins such
as U2AF35 (Fig. 4A). Deleting either the RS-rich domain
at the amino terminus (DRS) or sequences within the
linker (DL) abrogated the ability of U2AF65 to bind to
WT1, whereas U2AF35 binding was only lost following
deletion of linker sequences (Fig. 4B). This suggests that
both regions contribute to WT1 binding, and is sup-
ported by the finding that neither domain alone is suffi-
cient for WT1 association (data not shown).
To investigate whether WT1 plays an active role in
splicing a model system was set up. Nuclear extracts
were prepared from WT1-expressing M15 cells, and
shown to be competent for the splicing of a pre-mRNA
template, albeit less efficiently than HeLa extract (Fig.
5A). Large-scale splicing reactions containing biotinyl-
ated, 32P-labeled sense and antisense pre-mRNAs were
performed and fractionated, with the presence of specific
splicing complexes forming exclusively on the sense and
not antisense pre-mRNA as indicated by the shoulder on
the graph (Fig. 5B). This was confirmed by native gel
Figure 3. U2AF65 binding is independent of
dimerization, and affected by point mutation.
(A) Schematic representation of WT1 and de-
letion constructs. Four major isoforms are
generated by inclusion or exclusion of 17
amino acids and KTS, respectively. (*) Arg-to-
Trp substitution associated with DDS. (B,C).
Quantitation of b-galactosidase activity fol-
lowing transformation of yeast with U2AF65
(solid bars), SNF1 (open bars), and WT1+/+
(hatched bars, WT1+/+). Constructs carrying
the DDS mutation are marked D. The ability
of CDF1, CTF0, and F+KTS to dimerize was
not determined. (D) The percentage of WT1-
transfected Cos7 cells showing good colocal-
ization with splice factors.
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electrophoresis, a representative example of which is
shown in Figure 5C. Fractions were analyzed to detect
proteins present on the biotinylated pre-mRNA. WT1
was detected, like an established splicing factor, U2-B9,
specifically associated with the sense transcript (Fig. 5B),
providing evidence that WT1 can become incorporated
into spliceosomes.
Discussion
It has been demonstrated previously that WT1 colocal-
izes in the nucleus with splicing factors, and is present in
complexes with some spliceosomal components (Lars-
son et al. 1995). It has now been found that WT1 asso-
ciates specifically with U2AF65, in a manner enhanced
by three amino acids, KTS, inserted following alternative
pre-mRNA splicing. In addition WT1 can be incorpo-
rated directly into spliceosomes. These findings re-em-
phasize individual isoform properties, and provide evi-
dence of a new role for WT1 in pre-mRNA processing.
U2AF65 was identified from a series of splicing pro-
teins as a potential WT1-binding partner. Significantly,
U2AF65 was already a strong candidate for WT1 inter-
action following careful analysis of cell localization.
Both U2AF65 and WT1 show a nuclear ‘speckled’ pattern
characteristic of splicing factors. Unlike most splicing
factors U2AF65 localizes in ring-like structures around
nucleolar remnants when RNA synthesis is inhibited
with actinomycin D, and it was found that WT1 behaves
in a similar manner (Larsson et al.1995; Gama-Carvalho
e al. 1997). Interestingly +KTS forms of WT1, which
show best nuclear colocalization with splicing factors,
appear to interact more strongly with U2AF65, providing
an intriguing correlation between descriptive biology
and molecular properties. However, U2AF65 binding is
not essential for such a nuclear distribution, for example,
TF0 is unable to bind U2AF65 but displays a speckled
pattern. Nuclear ‘speckles’ contain splicing factors that
can apparently be recruited for active splicing (Misteli et
al. 1997), but can also contain splicing-defective factors
(Gama-Carvalho et al. 1997). This suggests that adoption
of a speckled distribution need not imply a functional
Figure 4. Both the amino-terminal RS do-
main and linker region of U2AF65 are re-
quired for WT1 binding. (A) Schematic repre-
sentation of U2AF65 and deletion constructs.
(B) Yeast was transformed with plasmids en-
coding the indicated proteins, and individual
colonies grown on Leu−Trp− media (left) prior
to the assessment of b-galactosidase activity
(right).
WT1 interacts with U2AF65
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role, as speckles might reflect storage sites for both ac-
tive and inactive splicing proteins. It is therefore possible
that WT1 proteins showing a speckled pattern fall into
two categories. One category may represent proteins
simply targeted to the speckles (for example, defective
mutants such as TF0), whereas a second category could
include functional proteins that can be recruited subse-
quently to participate in pre-mRNA processing. Experi-
ments are planned to investigate potential WT1 recruit-
ment from speckles and any correlation with U2AF65
binding.
Mapping the WT1 site to which U2AF65 binds has
identified the zinc-finger motif as essential. EGR1 with
its highly related zinc-finger structure does not appear to
interact with U2AF65, whereas binding of WT1 appar-
ently increased following KTS insertion. Interestingly a
reciprocal finding was presented recently, in which
−KTS WT1 had greatest affinity for the orphan nuclear
receptor SF-1 (Nachtigal et al. 1998). These results sug-
gest strongly that the +KTS and −KTS proteins adopt
different conformations. It is of particular interest that a
mutation found commonly in DDS patients affecting a
zinc-finger residue caused an apparent increase in
U2AF65 binding by the −KTS isoform. DDS is associated
generally with WT1 mutations in only one allele, the
disease seemingly arising in a dominant-negative man-
ner (Little and Wells). It has been envisaged that DDS
mutant proteins lose DNA-binding activity, and through
association with wild-type proteins could functionally
inactivate them. The loss of DNA binding by the −KTS
DDS protein, coupled with increased affinity for U2AF65
(an apparent gain of function) might better explain the
molecular basis for the disease. Frasier syndrome pa-
tients have mutations at splice-donor sites that specifi-
cally perturb the isoform ratio (Barbaux et al. 1997). The
current data suggests that the isoform ratio can be dis-
turbed phenotypically following dual loss/gain of func-
tion. It is interesting to note that in Frasier syndrome the
ratio is skewed so there becomes excess −KTS protein,
whereas in DDS there could be a phenotypic skew in the
opposite direction. This might be important when con-
sidering the major difference between the two; both DDS
and Frasier syndrome patients suffer genital abnormali-
ties and nephropathy but Frasier syndrome patients are
not apparently at risk of developing Wilms’ tumor per se.
Some DDS patients have WT1 truncations (Little and
Wells 1997) that can be shorter than TF0, however, and
would be anticipated to lose U2AF65 binding. More than
one mechanism may thus generate DDS.
The demonstration that WT1 could be incorporated
into spliceosomes assembled on a model template con-
nects the tissue-specific and developmentally regulated
protein not only with the splicing machinery, but with
splicing itself. U2AF65 is an essential splice factor that
binds to the polypyrimidine tract upstream of the 38
splice site and promotes U2 snRNA annealing to the
branch point (Zamore et al. 1992). Through interaction
with U2AF65, WT1 could therefore influence 38 splice-
site selection in a cell-type- and/or temporal-dependent
manner. The observations that WT1 potentially binds
RNA makes the prospect that WT1 might select a par-
ticular 38 splice site and present this directly to the RRM
of U2AF65 especially intriguing. U2AF65 contacts other
proteins, such as U2AF35, Urp, and SF1, which are im-
plicated in splice-site selection (Zamore et al. 1992; Abo-
vich and Rosbash 1997; Tronche´re et al. 1997). WT1
could compete with these proteins for binding, although
this seems unlikely for SF1, in which the binding site has
Figure 5. WT1 is incorporated into
spliceosomes. (A) Nuclear extracts were
prepared from WT1-expressing M15
cells, and their ability to splice a model
pre-mRNA compared to that of HeLa
extract. Control reaction C was set up
with inactive M15 extract. Splicing in-
termediates were resolved by PAGE and
detected by autoradiography. (B) Radio-
active tracing was used to follow the
fractionation of large-scale splicing re-
actions set up with sense (S) and anti-
sense (AS) pre-mRNAs. The indicated
fractions were pooled and streptavidin
beads used to capture proteins associ-
ated with the 32P-labeled biotinylated
RNA. Immunoblotting with the indi-
cated antibodies against WT1 or U2-B9
were used to determine protein distribu-
tion. Nuclear extract (NE) was loaded as
a positive control. (C) Native gel analy-
sis of a fractionated splicing reaction. A,
B+C, and H complexes are indicated. (*)
Nonspecific aggregates.
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been mapped to the third RRM of U2AF65 (Berglund et
al. 1998), a region not required for WT1 binding. Alter-
natively (or additionally), WT1 could affect the U2-an-
nealing activity of U2AF65, which occurs via recruit-
ment of UAP56 to the linker region (Fleckner et al.
1997). It is of interest that WT1 binding to U2AF65 ap-
pears to require sequences within the RS domain. The
RS domain of U2AF65 has different properties from a
classical RS domain (Valca´rcel et al. 1996) and WT1 does
not interact with other RS proteins, such as U2AF35.
The U2AF65 RS domain promotes RNA–RNA interac-
tion between the U2 snRNA and the branch point (Val-
ca´rcel et al. 1996) and it is possible that WT1 affects this
function of U2AF65. From the relative strength of WT1
signal in the U2AF65 and Sm immunoprecipitates, it is
clear that WT1 might interact with more than one com-
ponent of the splicing machinery. So far the analysis has
focused on specific proteins involved in the early stages
of spliceosome assembly, but it is possible that WT1 acts
at multiple stages during the splicing process. As
U2AF65 is specifically associated with early spliceo-
somes (Bennett et al. 1992), which are difficult to detect
by fractionation, perhaps WT1 is recruited initially to
the spliceosome via U2AF65, but then retained in later
complexes through interaction with other proteins. This
is an area of continued investigation.
An increasing number of connections have been made
between transcription and mRNA processing (Neuge-
bauer and Roth 1997), and it is particularly intriguing to
note the reciprocal properties of the WT1 isoforms. −KTS
proteins have stronger DNA-binding potential, and
weaker U2AF65-binding ability, whereas +KTS proteins
display less DNA binding but greater U2AF65 binding.
This emphasizes the effects a few amino acids can have
on the properties of a protein, but may also be important
when considering broader aspects of WT1 function. As
WT1 can dimerize (Reddy et al. 1995) one molecule with
strong DNA-binding activity could be coupled to one
with high U2AF65 affinity. Although the mechanism by
which WT1 represses or activates transcription is un-
clear, it is tempting to speculate that +KTS and −KTS
WT1 might cooperate to ensure not only that the correct
amount of a transcript is synthesized, but also that it is
spliced correctly. Although WT1 was incorporated into
spliceosomes on a model template, nothing is known
about genuine RNA targets of WT1. Nevertheless it is
easy to envisage how a protein that is able to influence
both transcription and splicing would play a critical role
in the control of proliferation and differentiation. The
precise effects of WT1 and the nature of its targets are
future questions, but the results presented here provide
direct evidence that WT1 plays a role in post-transcrip-
tional processing, changing the view that WT1 is specifi-
cally a transcription factor.
Materials and methods
Plasmids
Splice-factor cDNAs were cloned into pAS2 and WT1 into both
pAS2 and pACT2 (Harper et al. 1993) following PCR. Specific
WT1 isoforms are denoted by plus or minus symbols; the first
indicating the presence or absence of 17 amino acids and the
second KTS status. An NcoI site internal to the WT1 cDNA was
used to generate N180 and C ± KTS, encompassing or deleting
the first 180 amino acids, respectively. Other specific WT1 con-
structs were made by site directed mutagenesis or PCR. The
DDS mutation results in Arg-to-Trp substitution at amino acid
394. DF1 deletes residues 314–352, whereas TF0 is truncated at
amino acid 314. F + KTS was subcloned directly from
GST + KTS (Bickmore et al. 1992). EGR1 cDNA was provided
by V. Sukhatme (Beth Israel Hospital and Harvard Medical
School) and cloned in-frame using an NcoI site within the
cDNA (resulting in the loss of the first 28 residues). U2AF65 DN
contains amino acids 58–462, DRRM contains amino acids 1–
195, whereas residues 100–131 were deleted to create DL. For in
vitro translation, cDNAs were subcloned directly from the
yeast two-hybrid vector pACTII into pET11d (Novagen). For
transfection experiments, the appropriate constructs were
cloned into Rc/CMV (Invitrogen).
Antibodies
For immunohistochemistry, splicing proteins were detected
with 3C5 (Turner and Franchi 1987) followed by FITC anti-
mouse IgM, whereas raWT1 C19 (Santa Cruz) followed by rho-
damine anti-rabbit was used to detect WT1 [except TF0, which
was detected by maWT1 H2 (DAKO) followed by rhodamine
anti-mouse IgG]. For immunoprecipitation or Western blotting,
the following antibodies were used: H2 maWT1 (DAKO), C19
raWT1 (Santa Cruz), normal mouse IgG (Sigma), MC3
maU2AF65 (Gama-Carvalho et al. 1997), Y12 maSm proteins
(Lerner et al. 1981), 4g3 raU2-B88 (Habets et al. 1989).
Cell lines
M15 (Larsson et al. 1995) and Cos7 cells (ECACC) were cultured
at 37°C in DMEM supplemented with 10% FCS and in an at-
mosphere of 5% CO2.
Yeast two-hybrid analysis
Plasmids were introduced into yeast strain Y190 by lithium
acetate transformation, and interaction tested by growth on
leu−trp−his− media supplemented with 50 mM 3-amino triazole
(Harper et al. 1993). To assess b-galactosidase activity filter lifts
(from leu−trp− plates) and liquid assays (in leu−trp− media) were
performed as described (Harshman et al. 1988). b-galactosidase
activity was calculated: 1000 × A420/(volume × time × protein
concentration). At least three independent colonies from three
transformations were tested.
In vitro binding assays
GST–U2AF65 protein was prepared from bacteria according to
Lin and Green (1991). In vitro translated (IVT) protein was pre-
pared in a T7-driven rabbit reticulocyte-coupled transcription
and translation system (Promega). Five micrograms of bacteri-
ally expressed GST–U2AF65 was mixed with [35S]methionine-
labeled IVT protein in 200 µl of LSAB (100 mM NaCl, 100 mM
Tris at pH 8, 0.1% NP40) at 4°C for 2 hr. Complexes were
precipitated onto glutathione beads, washed extensively in
LSAB, resolved by SDS-PAGE and detected by fluorography. To
titrate the salt sensitivity of the GST–U2AF65:WT1 complex,
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reactions were performed as described above, increasing the salt
concentration in LSAB to 250 and 500 mM. The amount of bind-
ing to GST–U2AF65 was compared to binding to GST alone
following PhosphorImage analysis.
Immunofluorescence
Cos7 cells were electroporated (0.8 kV, 25 µF) with 5 µg of the
appropriate cytomegalovirus (CMV) driven construct. Cells
were fixed and stained 48 hr after transfection as described
(Larsson et al. 1995). Distribution of WT1 was superimposed on
the 3C5-staining pattern by dual-channel confocal microscopy.
Individual transfected cells were categorized by eye as display-
ing good, intermediate, or poor colocalization with splice fac-
tors. Thirty cells were scored per transfection, and the percent-
age of cells falling into each group calculated. Following at least
three independent transfections these proportions were aver-
aged.
Immunoprecipitation
Nuclear extracts from ~ 5 x 106 M15 cells were prepared accord-
ing to Kim et al. (1997), diluted 1:4 with IPB100 (100 mM NaCl,
10 mM Tris, 1 mM EDTA at pH 8), and precleared with protein
A-Sepharose before addition of the antibody cross-linked to pro-
tein A–Sepharose (Harlow and Lane 1988). Immune complexes
were washed extensively in IPB100 + 0.05% NP-40, and re-
solved by 8% SDS-PAGE. Proteins were transferred to nitrocel-
lulose by semidry transfer. Membranes were blocked with 5%
nonfat milk, and probed. Bound antibody was coupled to goat
anti-mouse/rabbit HRP as appropriate (Sigma), and detected by
ECL-plus (Amersham) according to the manufacturer’s instruc-
tions.
Splicing assays
Nuclear extract was prepared from 1 × 109 M15 cells according
to Dignam (1983). Adenovirus major late precursor (Konarska
and Sharp 1987) was used as a template and both 32P-labeled and
biotinylated during transcription. Sense pre-mRNA was made
from Sau3A-digested pBSAd1 with T3 RNA polymerase,
whereas antisense message used the same template, linearized
with HindIII, and transcribed with T7 polymerase. Splicing re-
actions were set up with 50% (vol/vol) nuclear extract, 1.5 mM
ATP, 2 mM MgCl2, 5 mM creatine phosphate, 2 mM DTT, 200
U/ml RNAsin (Promega), and 2.5 mg/ml pre-mRNA and left at
30°C for 2 hr. Splicing intermediates were separated on 10%
polyacrylamide–urea gel. For the fractionation experiments
(Reed et al. 1988), large-scale (10-ml) splicing reactions were set
up and after 30 min at 30°C loaded onto a 2.5 × 75-cm Sephacryl
S-500 column equilibrated with FSP (20 mM Tris at pH 7.8, 60
mM KCl, 2.5 mM EDTA, and 0.1% Triton X-100) at 4°C. Frac-
tions of 1.6 ml were collected at a flow rate of 0.4 ml/min. For
radioactive monitoring, 50 µl was taken from each and the as-
sembly of intact splicing complexes verified by native gel analy-
sis (3.5% polyacrylamide, 0.4% agarose). The appropriate frac-
tions were pooled, and supplemented to 2 mM DTT, 0.7 U/ml
RNasin, before mixing with streptavidin-coated beads (Boeh-
ringer) at 4°C. Bound complexes were washed extensively in 20
mM Tris at pH 7.9, 100 mM NaCl, prior to RNase A treatment.
Proteins were eluted with 20 mM Tris at pH 7.6, 20 mM DTT,
2% SDS, and precipitated with acetone, before SDS-PAGE.
Western blotting was performed as outlined above.
Acknowledgments
We thank T. Maniatis, G. Akusja¨rvi, V. Sukhatme, M. Green, J.
Steitz, B. Turner, and M. Carmo-Fonseca who generously pro-
vided reagents. A.I.L. is a Wellcome Trust Principal Research
Fellow. N.D.H. is an International Scholar of the Howard
Hughes Medical Institute.
The publication costs of this article were defrayed in part by
payment of page charges. This article must therefore be hereby
marked ‘advertisement’ in accordance with 18 USC section
1734 solely to indicate this fact.
References
Abovich, N. and M. Rosbash. 1997. Cross-intron bridging inter-
actions in the yeast commitment complex are conserved in
mammals. Cell 89: 403–412.
Barbaux, S., P. Niaudet, M.-C. Gubler, J.-P. Gru¨nfield, F. Jaubert,
F. Kuttenn, C.N. Fe´ke´te´, N. Souleyreau-Therville, E.
Thibaud, M. Fellous, and K. McElreavey. 1997. Donor splice-
site mutations in WT1 are responsible for Frasier syndrome.
Nat. Genet. 17: 467–470.
Berglund, J.A., N. Abovich, and M. Rosbash. 1998. A coopera-
tive interaction between U2AF65 and mBBP/SF1 facilitates
branchpoint recognition. Genes & Dev. 12: 858–867.
Bennett, M., S. Michaud, J. Kingston, and R. Reed. 1992. Protein
components specifically associated with prespliceosome and
spliceosome complexes. Genes & Dev. 6: 1986–2000.
Bickmore, W.A., K. Oghene, M.H. Little, A. Seawright, V. van
Heyningen, and N.D. Hastie. 1992. Modulation of DNA
binding specificity by alternative splicing of the Wilms’ tu-
mour wt1 gene transcript. Science 257: 235–237.
Bohmann, K., J.A. Ferreira, and A.I. Lamond. 1995. Mutational
analysis of p80 coilin indicates a functional interaction be-
tween coiled bodies and the nucleolus. J. Cell Biol. 131: 817–
831.
Breuning, W. and J. Pelletier. 1996. A non-AUG translational
initiation event generates novel WT1 isoforms. J. Biol.
Chem. 271: 8646–8654.
Caricasole, A., A. Duarte, S.H. Larsson, N.D. Hastie, M. Little,
G. Holmes, I. Todorov, and A. Ward. 1996. RNA binding by
the Wilms’ tumour suppressor zinc finger proteins. Proc.
Natl. Acad. Sci. 93: 7562–7566.
Dignam, J.D., R.M. Lebovitz, and R.G. Roeder. 1983. Accurate
transcription initiation by RNA polymerase II in a soluble
extract from isolated mammalian nuclei. Nucleic Acids Res.
11: 1475–1489.
Estojak, J., R. Brent, and E.A. Golemis. 1995. Correlation of
two-hybrid affinity data with in vitro measurements. Mol.
Cell. Biol. 15: 5820–5829.
Fleckner, J., M. Zhang, J. Valca´rcel, and M.R. Green. 1997.
U2AF65 recruits a novel human DEAD box protein required
for the U2 snRNP-branchpoint interaction. Genes & Dev.
11: 1864–1872.
Gama-Carvalho, M., R.D. Krauss, L. Chiang, J. Valca´rcel, M.R.
Green, and M. Carmo-Fonseca. 1997. Targeting of U2AF65 to
sites of active splicing in the nucleus. J. Cell Biol. 137: 975–
987.
Haber, D.A., R.L. Sohn, A.J. Buckler, J. Pelletier, K.M. Call, and
D.E. Housman. 1991. Alternative splicing and genomic
structure of the Wilms tumour gene WT1. Proc. Natl. Acad.
Sci. 88: 9618–9622.
Habets, W.J., M.H. Hoet, B.A.W. de Jong, A. van der Kemp, and
W.J. van Venrooij. 1989. Mapping of B cell epitopes on small
nuclear riboproteins that react with human autoantibodies
as well as with experimentally-induced mouse monoclonal
Davies et al.
3224 GENES & DEVELOPMENT
antibodies. J. Immunol. 143: 2560–2566.
Harlow, E. and D. Lane. 1988. Antibodies: A laboratory manual.
Cold Spring Habor Laboratory, Cold Spring Harbor, NY.
Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J.
Elledge. 1993. The p21 cdk-interacting protein is a potent
inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
Harshman, K.D., W.S. Moye-Rowley, and C.S. Parker. 1988.
Transcriptional activation by the SV40 AP-1 recognition el-
ement in yeast is mediated by a factor similar to AP-1 that is
distinct from GCN4. Cell 53: 321–330.
Hastie, N.D. 1994. The genetics of Wilms’ tumour—A case of
disrupted development. Annu. Rev. Biochem. 28: 523–558.
Kennedy, D., T. Ramsdale, J. Mattick, and M. Little. 1996. An
RNA recognition motif in Wilms’ tumour protein (WT1) re-
vealed by structural modelling. Nat. Genet. 12: 329–332.
Kent, J., A.-M. Coriat, P.T. Sharpe, N.D. Hastie, and V. van
Heyningen. 1995. The evolution of WT1 sequence and ex-
pression pattern in the vertebrates. Oncogene 11: 1781–
1792.
Kim, E., L. Du, D.B. Bregman, and S.L. Warren. 1997. Splicing
factors associate with hyperphosphorylated RNA polymer-
ase II in the absence of pre-mRNA. J. Cell Biol. 136: 19–28.
Konarska, M.M. and P.A. Sharp. 1987. Interactions between
small nuclear ribonuclear particles in formation of spliceo-
somes. Cell 49: 763–774.
Kreidberg, J.A.,H. Sariola, J. M. Loring, M. Maeda, J. Pelletier, D.
Housman, and R. Jaenisch. 1993. WT-1 is required for early
kidney development. Cell 74: 679–691.
Larsson, S.H., J.P. Charlieu, K. Miyagawa, D. Engelkamp, M.
Rassoulzadegan, A. Ross, F. Cuzin, V. van Heyningen, and
N.D. Hastie. 1995. Subnuclear localisation of WT1 in splic-
ing or transcription factor domains is regulated by alterna-
tive splicing. Cell 81: 391–401.
Lerner, E.A., M.R. Lerner, C.A. Janeway, and J.A. Steitz. 1981.
Monoclonal antibody to nucleic acid-containing cellular
constituents: Probes for molecular biology and autoimmune
disease. Proc. Natl. Acad. Sci. 78: 2737–2741.
Lin, Y.S. and M.R. Green. 1991. Mechanism of action of an
acidic transcriptional activator in vitro. Cell 64: 971–981.
Little M. and C. Wells. 1997. A clinical overview of WT1 gene
mutations. Hum. Mut. 9: 209–225.
Misteli, T., J. Ca´ceres, and D.L. Spector. 1997. The dynamics of
a pre-mRNA splicing factor in living cells. Nature 387: 523–
527.
Nachtigal, M.W., Y. Hirokawa, D.L. Enyeart-VanHouten, J.N.
Flanagan, G.D. Hammer and H.A. Ingraham. 1998. Wilms’
tumour 1 and Dax-1 modulate the orphan nuclear receptor
SF-1 in sex-specific gene expression. Cell 93: 445–454.
Neugebauer, K.M. and M.B. Roth. 1997. Transcription units as
RNA processing units. Genes & Dev. 11: 3279–3285.
Pritchard-Jones, K., S. Fleming, D. Davidson, W. Bickmore, D.
Porteous, C. Gosden, J. Bard, A. Buckler, J. Pelletier, D.
Housman, V. van Heyningen, and N. Hastie. 1990. The can-
didate Wilms’ tumour gene is involved in genitourinary de-
velopment. Nature 346: 194–197.
Rauscher, F.J., J.F. Morris, O.E. Tounay, D.M. Cook, and T.
Curran. 1990. Binding of the Wilms’ tumour locus zinc fin-
ger protein to the EGR-1 consensus sequence. Science
250: 1259–1262.
Reddy, J.C., J.C. Morris, J. Wang, M.A. English, D.A. Haber, Y.
Shi, and J.D. Licht. 1995. WT1-mediated transcriptional ac-
tivation is inhibited by dominant negative mutant proteins.
J. Biol. Chem. 270: 10878–10884.
Reed, R., J. Griffith, and T. Maniatis. 1988. Purification and
visualisation of native spliceosomes. Cell 53: 949–961.
Sharma, P.M., M. Bowman, S.L. Madden, F.J. Rauscher, and S.
Sukumar. 1994. RNA editing in the Wilms’ tumor suscepti-
bility gene, WT1. Genes & Dev. 8: 720–731.
Tronche`re, H., J. Wang, and X.-D. Fu. 1997. A protein related to
splicing factor U2AF35 that interacts with U2AF65 and SR
proteins in splicing of pre-mRNA. Nature 388: 397–400.
Turner, B.M. and L. Franchi. 1987. Identification of protein an-
tigens associated with the nuclear matrix and with clusters
of interchromatin granules in both interphase and mitotic
cells. J. Cell Sci. 87: 269–282.
Valca´rcel, J., R.K. Gaur, R. Singh, and M.R. Green. 1996. Inter-
action of U2AF65 RS region with pre-mRNA branchpoint
and promotion of base pairing with U2 snRNA. Science
273: 1706–1709.
Wang, Z.Y., Q.Q. Qiu, and T.F. Dueul. 1993. The Wilms’ tu-
mour gene product WT1 activates or represses transcription
through separate functional domains. J. Biol. Chem. 268:
9172–9175.
Wu, J.Y. and T. Maniatis. 1993. Specific interactions between
proteins implicated in splice site selection and regulated al-
ternative splicing. Cell 75: 1061–1070.
Zamore, P.D., J.G. Patton, and M.R. Green. 1992. Cloning and
domain structure of the mammalian splicing factor U2AF.
Nature 355: 609–614.
WT1 interacts with U2AF65
GENES & DEVELOPMENT 3225
